Industry Symposium 33

30 Mar 2026 8:10 a.m. 9:10 a.m.
304
KenjiIshikura Chair Japan

Session Title:  Evaluating new treatment options for chronic kidney disease in children: the EMPA-KIDNEY KIDS trial

Organized By : Boehringer Ingelheim GmbH

Session Description : 

Chronic kidney disease (CKD) in children has a significant impact on morbidity, mortality, and quality of life, in addition to effects on growth and neurocognitive development. There are significant differences in the underlying etiology and prevalence of CKD in children compared with adults. Furthermore, diagnosis and screening are complicated by age-specific changes in glomerular filtration rate.
 
In this session, an international faculty of expert nephrologists will outline the key challenges facing clinicians when screening, diagnosing and treating children with chronic kidney disease, and will describe approaches for clinical trials in this patient population.

Learning Objectives :

1. Attendees will have a greater understanding of the unmet needs in screening, diagnosing and treating chronic kidney disease in pediatric patients

2. Attendees will understand the challenges in designing a clinical trial in this patient population